Want to see JP:4502 full AI Analyst Report?
Total Valuation
Takeda Pharmaceutical Co has a market cap or net worth of ¥8.80T. The enterprise value is ¥12.75M.
Market Cap¥8.80T
Enterprise Value¥12.75M
Share Statistics
Takeda Pharmaceutical Co has 1,602,047,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,602,047,600
Owned by Insiders0.20%
Owned by Institutions<0.01%
Financial Efficiency
Takeda Pharmaceutical Co’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.95%.
Return on Equity (ROE)0.02
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)2.95%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee95.81M
Profits Per Employee4.08M
Employee Count47,029
Asset Turnover0.29
Inventory Turnover1.58
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Co is 129.5. Takeda Pharmaceutical Co’s PEG ratio is 0.60.
PE Ratio129.5
PS Ratio1.98
PB Ratio1.15
Price to Fair Value1.15
Price to FCF11.70
Price to Operating Cash Flow9.20
PEG Ratio0.60
Income Statement
In the last 12 months, Takeda Pharmaceutical Co had revenue of 4.51T and earned 191.76B in profits. Earnings per share was 121.75.
Revenue4.51T
Gross Profit2.30T
Operating Income540.45B
Pretax Income260.19B
Net Income191.76B
EBITDA1.34T
Earnings Per Share (EPS)121.75
Cash Flow
In the last 12 months, operating cash flow was 894.89B and capital expenditures -194.63B, giving a free cash flow of 700.26B billion.
Operating Cash Flow894.89B
Free Cash Flow700.26B
Free Cash Flow per Share437.10
Dividends & Yields
Takeda Pharmaceutical Co pays an annual dividend of ¥102, resulting in a dividend yield of 3.63%
Dividend Per Share¥102
Dividend Yield3.63%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.38
52-Week Price Change29.38%
50-Day Moving Average5.23K
200-Day Moving Average5.06K
Relative Strength Index (RSI)43.20
Average Volume (3m)4.35M
Important Dates
Takeda Pharmaceutical Co upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Takeda Pharmaceutical Co as a current ratio of 1.27, with Debt / Equity ratio of 65.36%
Current Ratio1.27
Quick Ratio0.70
Debt to Market Cap0.55
Net Debt to EBITDA3.20
Interest Coverage Ratio1.51
Taxes
In the past 12 months, Takeda Pharmaceutical Co has paid 68.16B in taxes.
Income Tax68.16B
Effective Tax Rate0.26
Enterprise Valuation
Takeda Pharmaceutical Co EV to EBITDA ratio is 9.86, with an EV/FCF ratio of 17.32.
EV to Sales2.93
EV to EBITDA9.86
EV to Free Cash Flow17.32
EV to Operating Cash Flow14.07
Balance Sheet
Takeda Pharmaceutical Co has ¥527.58B in cash and marketable securities with ¥4.94T in debt, giving a net cash position of -¥4.41T billion.
Cash & Marketable Securities¥527.58B
Total Debt¥4.94T
Net Cash-¥4.41T
Net Cash Per Share-¥2.75K
Tangible Book Value Per Share-¥922.86
Margins
Gross margin is 62.15%, with operating margin of 11.99%, and net profit margin of 4.26%.
Gross Margin62.15%
Operating Margin11.99%
Pretax Margin5.77%
Net Profit Margin4.26%
EBITDA Margin29.72%
EBIT Margin13.71%
Analyst Forecast
The average price target for Takeda Pharmaceutical Co is ¥6,500.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target¥6,500.00
Price Target Upside15.08% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast3.10%
EPS Growth Forecast-218.63%